

Medical Medication PA Updates and New Requirements

Learn about prior authorization (PA) changes in this update

The following pages have PA changes for Medi-Cal fee-for-service physicians and other providers.

AMA and CMS New Current Procedural Terminology (CPT®) and Healthcare Common Procedure Coding System (HCPCS)

The below medical benefit medications and proprietary laboratory analyses (PLA) services require PA per new CPT and HCPCS codes issued by the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS).

Effective July 1, 2024

Code	Description	Brand/reference
J1748	Injection, infliximab-dyyb (Zymfentra), 10 mg.	Self-Injectable: Zymfentra
J2267	Injection, mirikizumab-mrkz, 1 mg.	Omvoh™
J3247	Injection, secukinumab, IV, 1 mg.	Cosentyx®
J3393	Injection, betibeglogene autotemcel, per treatment.	Loqtorzi™
J3394	Injection, lovetibeglogene autotemcel, per treatment.	Zynteglo™
J7171	Injection, ADAMTS13, recombinant-krhn, 10 IU.	Lyfgenia™
J7355	Injection, travoprost, intracameral implant, 1 mcg.	Adzyna™
J9361	Injection, efbemalenograstim alfa-vuxw, 0.5 mg.	iDose® TR (implant)

THIS UPDATE APPLIES TO:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Support (CS) Providers
- Enhanced Care Management (ECM) Providers
- Behavioral Health Providers

PROVIDER SERVICES

CalViva Health Medi-Cal (including ECM and CS providers) –
888-893-1569

Behavioral health providers –
844-966-0298

PROVIDER PORTAL

provider.healthnetcalifornia.com

New HCPCS Codes, continued

Effective July 1, 2024

Code	Description	Brand/reference
Q5137	Injection, ustekinumab-auub (Wezlana), biosimilar, SC, 1 mg.	Ryzneuta™
Q5138	Injection, ustekinumab-auub (Wezlana), biosimilar, IV, 1 mg.	Self-injectable: Wezlana™

New CPT Codes

Effective July 1, 2024

CPT Copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

Code	Description
0457U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative.
0459U	B-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology.
0462U	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary.
0468U	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis.
0472U	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiquantitative, blood, reported as predictive evidence of early Sjogren syndrome.

PA changes and deletions

View the tables below for PA requirements changes for Health Net* and CalViva Health physicians and other providers.

Medical Services and Outpatient Pharmaceuticals (Submitted under Medical Benefit)

Change

The following requires PA.

Benefit	Authorization required
Dental anesthesia	<ul style="list-style-type: none">• CPT 00170 – anesthesia on mouth for Current Dental Terminology procedures.• CPT 00190 – anesthesia for procedures on the head.• Reference prior communication – Find Out What Changed: Sedation and Anesthesia Coverage for Dental Services for Community Health Plan of Imperial Valley at providerlibrary.healthnetcalifornia.com/news/24-108M-Find-Out-What-Changed-Sedation-and-Anesthesia-Coverage-for-Dental-Services.html.

Deletions, effective immediately

The following no longer require PA.

Benefit	Change
Adulhelm™	J0172, injection, aducanumab-avwa, 2 mg. Product discontinued.
Retacrit™	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5105 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units.• Q5106 Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units.
Zarxio®	No longer requires PA when administered/provided under the medical benefit. ¹ <ul style="list-style-type: none">• Q5101, Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg.
Sobering Centers	Update to the Authorization Guidelines for Sobering Centers – go to bit.ly/CalAIM_Resources . Select <i>Forms & Tools > Community Supports</i> , scroll down to Authorization Guides and click on Sobering Centers under <i>CalViva Health</i> .

¹PA is required when administered/provided under the pharmacy benefit.

Clinical trials

To receive urgent status for routine services requiring authorization that are related to a clinical trial, please either include the attestation form in your prior authorization request or indicate 'Routine Care Cost Services Associated with the Clinical Trial.' The state attestation form for clinical trials can be accessed at bit.ly/Attest-Clinical_Trial.

For more information about [clinical trials](#), go to the Provider Library and select *Medi-Cal > Provider Manual > Benefits > Clinical Trials > Routine Care Costs for Qualifying Clinical Trials*.

Additional information

Providers are encouraged to access the provider portal at provider.healthnetcalifornia.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569. Behavioral Health providers can call at 844-966-0298.